AT1019 injections with focused radiation and PD-1 immunotherapy for advanced solid tumors

A Phase I Investigator-Initiated Trial (IIT) of AT1019 Combined With Stereotactic Body Radiation Therapy (SBRT) and PD-1 Inhibitor for Advanced Solid Tumors

This will test whether giving injected AT1019 together with focused radiation (SBRT) and a PD‑1 immunotherapy is safe and tolerable for adults with advanced solid tumors.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: The Affiliated Hospital of Xuzhou Medical University (other)
• Drugs / interventions: immunotherapy, radiation
• Locations: 1 site (Xuzhou, Jiangsu)
• Trial ID: NCT07285395 on ClinicalTrials.gov

What this trial studies

This is a Phase 1, investigator-initiated dose-finding trial testing intratumoral AT1019 combined with standard PD‑1 inhibitor treatment and stereotactic body radiation therapy (SBRT). Patients receive PD‑1 inhibitor as scheduled, SBRT in 3–5 weekly fractions of 6–18 Gy, and intratumoral AT1019 injections 1–2 days after each SBRT session. The main goals are to characterize safety, tolerability, and to determine the maximum tolerated dose (MTD) of AT1019 in this combination. Tumor response and safety will be monitored with imaging every six weeks and standard clinical and laboratory assessments.

Who should consider this trial

Good fit: Adults (≥18) with advanced solid tumors who are receiving PD‑1 immunotherapy, have lesions suitable for SBRT, have at least stable disease on prior immunotherapy, ECOG performance status ≤1, and adequate organ and marrow function are eligible.

Not a fit: Patients with poor performance status (ECOG >1), significant organ dysfunction, active cardiac conduction/ischemia issues, or tumors not amenable to SBRT are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the combination could improve local tumor control and boost immune response to help shrink tumors beyond what PD‑1 therapy or radiation achieve alone.

How similar studies have performed: Combining radiation with PD‑1 inhibitors has shown promising signals in other studies, but intratumoral AT1019 is a novel element with limited prior clinical data.

Eligibility criteria

Inclusion Criteria:

1. Male or female patients aged ≥ 18 years.
2. Signed the informed consent form and have the psychological capacity to understand it.
3. Patients with advanced solid malignant tumors (such as non-small cell lung cancer, renal cell carcinoma, head and neck cancer, cervical cancer, and urothelial carcinoma) who are receiving immunotherapy and planned to undergo SBRT. Patients are eligible if they achieved at least stable disease during previous immunotherapy.
4. Patients' disease must be evaluated according to RECIST v.1.1.
5. Presence of metastatic lesions amenable to radiation therapy.
6. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1.
7. No evidence of clinically significant conduction abnormalities or active ischemia on electrocardiogram (ECG), as judged by the investigator.
8. Acceptable organ and bone marrow function as demonstrated by the following criteria:

(1) Absolute neutrophil count \> 1500 cells/μL; (2) Platelet count \> 50,000 cells/μL; (3) Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); (4) Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 times the ULN; if hepatic metastasis exists, AST/ALT \< 5 times the ULN; (5) Serum creatinine \< 1.5 mg/dL and creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula; (6) Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times the ULN.

9\. Females of childbearing potential (defined as those who have experienced menarche and have not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are not postmenopausal (defined as at least 12 months of amenorrhea with appropriate clinical documentation, such as age \> 45 years)) must undergo a serum pregnancy test prior to the first administration of study treatment and confirm a negative result.

10\. Male and female patients of childbearing potential must agree to use two effective contraceptive methods throughout the study period.

Exclusion Criteria:

1. Previous therapeutic radiotherapy to the same lesion.
2. Failure to recover to grade 1 or lower from clinically significant adverse events related to prior anticancer therapy, as judged by the investigator.
3. Previous grade 4 toxicity attributed to immunotherapy.
4. Known untreated brain metastases or treated but unstabilized brain metastases (central nervous system lesions shown on scan to be non-progressive and not requiring corticosteroid use) ≥ 4 weeks prior to enrollment.
5. QT/QTc interval prolongation (QTc interval \> 470 milliseconds).
6. Uncontrolled intercurrent illnesses (including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or psychiatric/social conditions) that, in the investigator's judgment, would limit the patient's compliance with study requirements.
7. Pregnant or lactating women.
8. The Sponsor reserves the right to exclude any patient based on pre-study medical history, physical examination findings, clinical laboratory results, prior medications, or other enrollment criteria.

Where this trial is running

Xuzhou, Jiangsu

• The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu, China (RECRUITING)

Study contacts

• Study coordinator: Hui Qiu, M.D., Ph.D.

Conditions: Advanced Solid Tumors